drugset / Trial / NCT03878953

A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism

NCT03878953

Phase 3 Withdrawn Shire
NaSingle-groupOpen-labelTreatment

Summary

This clinical study aims to evaluate the safety and efficacy of repeated dosing of recombinant human parathyroid hormone (rhPTH\[1-84\]) in Japanese participants with chronic hypoparathyroidism for a 26-week period.

Timeline

Start
2022-08-31
Primary completion
2023-05-31
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Parathyroid Hormone Protein / enzyme biologic 50 ug Subcutaneous

Indications